News Search Results
Dec 03, 2025, 10:00 ET Florida Cancer Specialists & Research Institute Contributing To Breakthroughs In Treatment of Blood Cancers & Disorders
inhibitor approved by the U.S. Food & Drug Administration (FDA) in 2023 for mantle cell lymphoma (MCL), followed shortly by approvals for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In 2024, the FDA approved revumenib—a revolutionary therapy for relapsed or refractory
More news about: Florida Cancer Specialists & Research Institute
Dec 03, 2025, 08:30 ET Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting
Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ (PhasED-Seq) minimal residual disease (MRD) analysis at the 67th American Society of Hematology (ASH) Annual
More news about: Foresight Diagnostics, Inc.
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily
More news about: ADC Therapeutics SA
Dec 02, 2025, 16:05 ET ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
More news about: ADC Therapeutics SA
Dec 02, 2025, 14:00 ET Blood Cancer United, formerly The Leukemia & Lymphoma Society, Announces New Funding for Lifesaving Cancer Breakthroughs
Spain, leads a $6.5 million alliance, supported by Blood Cancer United and the Institute for Follicular Lymphoma Innovation through our partnership, the Research Accelerator for Follicular Lymphoma. This award funds the ERADICATE alliance under Dr. Melnick's leadership, uniting world-class researchers
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Dec 02, 2025, 10:00 ET FOUNDERS DAVE COULIER & PAT GREENE ANNOUNCE NEW DIGITAL MARKETPLACE FOR TOXIN-FREE, HOLISTIC WELLNESS PRODUCTS AWEARMARKET.COM
products. AwearMarket was born from a deeply personal chapter in Dave's life. In October 2024, he publicly shared his diagnosis of stage 3 Non-Hodgkin Lymphoma."AwearMarket grew out of one of the toughest moments of my life, but also one of the most eye-opening," said Dave Coulier. "When I started focusing
More news about: AwearMarket
Dec 02, 2025, 09:00 ET Applied Underwriters Invitational Nets Record-Breaking $15.2 Million for Charities from this Year's Expanded National Golf Tournament Series, World's Largest
said."We are proud to support so many charities, including Boys & Girls Clubs, the Habitat for Humanity, the United Way, the Leukemia and Lymphoma Society, Chinese Hospital of San Francisco, Wide Horizons for Children, Reimagine Life Foundation, the Addiction Education Society, the Autism Society,
More news about: Applied Underwriters
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
showcasing continued advances in research across multiple blood cancers including — multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Data across AbbVie's blood cancer portfolio will be
More news about: AbbVie Inc.
Dec 02, 2025, 08:00 ET Rutgers Cancer Institute and RWJBarnabas Health to Showcase Practice-Changing Blood Cancer Research at the 67th American Society of Hematology Annual Meeting and Exposition
New data offers impactful clinical insights across Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and real-world disparities analysesNEW BRUNSWICK, N.J., Dec. 2, 2025
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Dec 01, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Dec 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In
More news about: ADC Therapeutics SA
Dec 01, 2025, 12:00 ET Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
approved by the FDA in August 2024.About Cutaneous T-cell LymphomaCutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the
More news about: Citius Oncology, Inc.
Dec 01, 2025, 08:00 ET Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
Blood Cancer United®—formerly The Leukemia & Lymphoma Society—will celebrate new data presented by Blood Cancer United funded grantees at the upcoming American Society of Hematology (ASH) Annual Meeting
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Dec 01, 2025, 07:00 ET Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Nov 26, 2025, 17:31 ET Mycosis Fungoides Market Set to Expand by 2034 with Advancements in Targeted and Immunotherapy Approaches | DelveInsight
Cutaneous T-cell Lymphoma MarketCutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease,
More news about: DelveInsight Business Research, LLP
Nov 26, 2025, 01:48 ET Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
therapy. Most of the patients were receiving concomitant immunosuppressants.Post-marketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease
More news about: Celltrion
Nov 25, 2025, 09:00 ET Caring Cross and Amrita Research Center Delhi, Amrita Vishwa Vidyapeetham Announce Strategic Partnership to Advance Affordable Cell and Gene Therapies for Underserved Populations Across India
designed to reduce the cost of delivering cures at the point of care. This includes advancing TriCAR-T cell therapies for the treatment of Leukemia and Lymphoma, and other next-generation affordable CGT platforms focused on equitable access."This partnership shares a critical mission: to dismantle the
More news about: Caring Cross
Nov 25, 2025, 08:00 ET Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
approved by the FDA in August 2024.About Cutaneous T-cell LymphomaCutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the
More news about: Citius Oncology, Inc.
Nov 24, 2025, 12:00 ET Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy,
More news about: Eli Lilly and Company
Nov 24, 2025, 06:03 ET Cell Therapy Market Size Set to More Than Double by 2030 -- North America Leads, While Asia-Pacific Emerges as the Fastest-Growing Region, Says Mordor Intelligence
Market is Segmented by Target Antigen (CD19, BCMA, CD22, GD2), Type (Abecma, Breyanzi), Cell Source (Autologous and Allogenic), Application (Leukemia, Lymphoma), End User (Hospitals, Cancer Care Treatment Centers), and Geography (North America, Europe, Asia-Pacific).Novartis AG, Bristol-Myers Squibb
More news about: Mordor Intelligence Private Limited
Nov 21, 2025, 17:32 ET Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
also highlighted his team's progress on armored CAR-T programs—such as IL-18 and IL-9 constructs—which are showing encouraging activity in refractory lymphoma and in a pancreatic cancer mouse model. He noted that improving CAR-T infiltration and durability in solid tumors remains a core challenge, while
More news about: GenScript Biotech Corporation
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7 (ABSTRACT 25-2787) Liquid-biopsy mutation landscape and its concordance with skin biopsies in cutaneous T-cell lymphoma (ABSTRACT 25-2858) ZUMA-25 preliminary
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 21, 2025, 08:37 ET Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
approved by the FDA in August 2024.About Cutaneous T-cell LymphomaCutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the
More news about: Citius Oncology, Inc.
Nov 20, 2025, 10:12 ET PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) and r/r B-cell Non-Hodgkin Lymphoma (B-NHL), including patients who failed prior CD19-directed therapy or presented with CD19-negative disease. Interim results from the Phase 1 dose-escalation
More news about: PeproMene Bio, Inc.
Nov 20, 2025, 10:12 ET PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) and r/r B-cell Non-Hodgkin Lymphoma (B-NHL), including patients who failed prior CD19-directed therapy or presented with CD19-negative disease. Interim results from the Phase 1 dose-escalation
More news about: PeproMene Bio, Inc.